Company news
Oncoinvent Asa (OSL:ONCIN) news
Oncoinvent Asa news releases on 6ix. Latest, Sep 23, 2026: Oncoinvent ASA - Disclosure of large shareholding
Press releases & updates
Oncoinvent ASA - Disclosure of large shareholding
September 23, 2026
Oncoinvent ASA - Mandatory notification of trade - Allocation and share lending in Private Placement
September 22, 2026
Oncoinvent ASA - Mandatory notification of trade
September 22, 2026
Oncoinvent ASA - Key information relating to subsequent offering
September 22, 2026
Oncoinvent ASA - Successful Private Placement and Retail Offering
September 22, 2026
Oncoinvent ASA - Contemplated private placement and retail offering
September 22, 2026
Oncoinvent announces publication of normal tissue dosimetry results in Journal of Nuclear Medicine
August 11, 2026
Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin[®]
June 18, 2026
Oncoinvent ASA: Grant of share options to member of the Board following AGM
May 20, 2026
Oncoinvent ASA: Share capital decrease completed
May 5, 2026
Oncoinvent presents corporate update in live webcast
April 29, 2026
Oncoinvent ASA: Notice of Annual General Meeting
April 28, 2026
Oncoinvent ASA: Invitation to business update Wednesday 29 April 2026
April 23, 2026
Oncoinvent ASA: Annual Report for 2025
April 22, 2026
Oncoinvent secures new patent expanding protection for Radspherin[®]
March 19, 2026
Oncoinvent ASA: Grant of share options to the CEO
March 11, 2026
Oncoinvent ASA: Second half 2025 results
February 26, 2026
Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin[®] at ESGO 2026
February 17, 2026
Oncoinvent ASA, Announces webcast presentation of second half 2025 results on Thursday 26 February 2026
February 16, 2026
Oncoinvent ASA: Announces webcast presentation of second half 2025 results on Thursday 26 February 2026
February 16, 2026
Four additional sites open for recruitment in Oncoinvent's Phase 2 trial
January 29, 2026
Oncoinvent ASA: Registration of reverse share split
January 20, 2026
Oncoinvent ASA: Ex. reverse share split and change of ISIN today
January 19, 2026
Oncoinvent ASA, Key information relating to the reverse share split and Change of ISIN
January 15, 2026
Oncoinvent ASA - New share capital registered
January 15, 2026
Oncoinvent ASA: Key information relating to the reverse share split and change of ISIN
January 14, 2026
Oncoinvent ASA, Grant of share options to new CFO
January 14, 2026
Oncoinvent ASA: Grant of share options to new CFO
January 13, 2026
Oncoinvent ASA: Grant of share options – mandatory notification of trade
December 22, 2025
Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer
October 8, 2025
Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer
August 27, 2025
Announcement of fully underwritten rights issue
June 30, 2025